Natural Killer Cell-Based Immunotherapy against Glioblastoma

Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS) after diagnosis is approximately 2 years and the 5-year OS...

Descripción completa

Detalles Bibliográficos
Autores principales: Morimoto, Takayuki, Nakazawa, Tsutomu, Maeoka, Ryosuke, Nakagawa, Ichiro, Tsujimura, Takahiro, Matsuda, Ryosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916747/
https://www.ncbi.nlm.nih.gov/pubmed/36768432
http://dx.doi.org/10.3390/ijms24032111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916747/
https://www.ncbi.nlm.nih.gov/pubmed/36768432
http://dx.doi.org/10.3390/ijms24032111

Ejemplares similares